Cancer Immunotherapy Program
The magic of small-molecule drugs during ex vivo expansion in adoptive cell therapy. Zhang H, Passang T, Ravindranathan S, Bommireddy R, Jajja MR, Yang L, Selvaraj P, Paulos CM, Waller EK. Front Immunol., 2023 Apr 21;14:1154566. doi:10.3389/fimmu.2023.1154566. PubMed PMID: 37153607; PubMed Central PMCID: PMC10160370
Metformin Reduces PD-L1 on Tumor Cells and Enhances the Anti-tumor Immune Response Generated by Vaccine Immunotherapy. Muñoz LE, Huang L, Bommireddy R, Sharma R, Monterroza L, Guin RN, Samaranayake S, Pack CD, Ramachandiran S, Reddy SJC, Shanmugam M, Selvaraj P. J Immunother Cancer, 2021. 9:e002614. doi:10.1136/jitc-2021-002614. PubMed PMID: 34815353; PubMed Central PMCID: PMC8611422
Dendritic cells pulsed with cytokine-adjuvanted tumor membrane vesicles inhibit tumor growth in HER2-Positive and Triple Negative Breast Cancer Models. Muñoz LE, Monterroza L, Bommireddy R, Shafizadeh Y, Pack CD, Ramachandiran S, Reddy SJC, Selvaraj P. International Journal of Molecular Sciences, 2021. 22(16), 8377. PubMed PMID: 34445092; PubMed Central PMCID: PMC8395038
Tumor membrane-based vaccine immunotherapy in combination with anti-CTLA-4 antibody confers protection against immune checkpoint resistant murine triple negative breast cancer. Pack CD, Bommireddy R, Muñoz LE, Patel JM, Bozeman EN, Dey P, Radhakrishnan V, Vartabedian VF, Venkat K, Ramachandiran S, Reddy S JC, Selvaraj P. Human Vaccines & Immunotherapeutics, 2020. DOI: 10.1080/21645515.2020.1754691. PubMed PMID: 32530786
Tumor membrane vesicle vaccine augments the efficacy of anti-PD-1 antibody in immune checkpoint inhibitor-resistant squamous cell carcinoma models of head and neck cancer. Bommireddy R, Muñoz LE, Kumari A, Huang L, Fan Y, Monterroza L, Pack CD, Ramachandiran S, Reddy SJC, Kim J, Chen ZG, Saba NF, Shin DM, Selvaraj P. Vaccines, 2020. 8(2):182. PubMed PMID: 32295135; PubMed Central PMCID: PMC7348725
Therapeutic efficacy of PD-L1 blockade in a breast cancer model is enhanced by cellular vaccines expressing B7-1 and glycolipid-anchored IL-12. Bozeman EN, He S, Shafizadeh Y, Selvaraj P. Human Vaccines & Immunotherapeutics, 2016. 12:421-30. PubMed PMID: 26308597; PubMed Central PMCID: PMC5049731
Plasma membrane vesicles decorated with glycolipid-anchored antigens and adjuvants via protein transfer as an antigen delivery platform for inhibition of tumor growth. Patel JM, Vartabedian VF, Bozeman EN, Caoyonan BE, Srivatsan S, Pack CD, Dey P, D’Souza MJ, Yang L, Selvaraj P. Biomaterials, 2016. 74:231-244. PubMed PMID: 26461116; PubMed Central PMCID: PMC4661141
Expression of membrane anchored cytokines and B7-1 alters tumor microenvironment and induces protective antitumor immunity in a murine breast cancer model. Bozeman EN, Cimino-Mathews A, Machiah DK, Patel JM, Krishnamoorthy A, Tien L, Shashidharamurthy R, Selvaraj P. Vaccine, 2013. 31:2449-56. PubMed PMID: 23541884; PubMed Central PMCID: PMC3686649
Human tumor membrane vesicles modified to express glycolipid-anchored IL-12 by protein transfer induce T cell proliferation in vitro: a potential approach for local delivery of cytokines during vaccination. Nagarajan S, Selvaraj P. Vaccine, 2006. 24:2264-74. PubMed PMID: 16376465
Development of therapeutic vaccines by direct modification of cell membranes from surgically removed human tumor tissue with immunostimulatory molecules. Poloso NJ, Nagarajan S, Bumgarner GW, Selvaraj P. Vaccine, 2001. 19:2029-38. PubMed PMID: 11228374
Protein transfer of glycosyl-phosphatidylinositol-B7-1 into tumor cell membranes: a novel approach to tumor immunotherapy. McHugh RS, Nagarajan S, Wang YC, Sell KW, Selvaraj P. Cancer Research, 1999. 59:2433-7. PubMed PMID: 10344754
Vaccine Adjuvant Program
Hemagglutinin virus-like particles incorporated with membrane-bound cytokine adjuvants provide protection against homologous and heterologous influenza virus challenge in aged mice. Park BR, Bommireddy R, Chung DH, Kim K-H, Subbiah J, Jung Y-J, Bhatnagar N, Pack CD, Ramachandiran S, Reddy SJC, Selvaraj P, Kang SM. Immunity & Ageing, 2023, 20: 20. Pubmed PMID: 37170231. PubMed Central PMCID: PMC10173218.
Influenza Virus-like Particle-Based Hybrid Vaccine Containing RBD Induces Immunity against Influenza and SARS-CoV-2 Viruses. Bommireddy R, Stone S, Bhatnagar N, Kumari P, Muñoz LE, Oh J, Kim K-H, Berry JTL, Jacobsen KM, Jaafar L, Naing SH, Blackerby AN, Van der Gaag T, Wright CN, Lai L, Pack CD, Ramachandiran S, Suthar MS, Kang SM, Kumar M, Reddy SJC, Selvaraj P. Vaccines, 2022.10: 944. Pubmed PMID: 35746552. PubMed Central PMCID: PMC9230705.
Protein transfer-mediated surface engineering to adjuvantate virus-like nanoparticles for enhanced anti-viral immune responses. Patel JM, Kim MC, Vartabedian VF, Lee YN, He S, Song JM, Choi HJ, Yamanaka S, Amaram N, Lukacher A, Montemagno CD, Compans RW, Kang SM, Selvaraj P. Nanomedicine, 2015.11(5):1097-107. Pubmed PMID: 25752855. PubMed Central PMCID: PMC4512837.